Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MOK | Q9UQ07 | 14/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP2A13 | Q16696 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475326 | 0.86 | L3MBTL1 (0.50) | MOKNPC1RAB9APAX8L3MBTL1 | |
| SCHEMBL19475336 | 0.83 | MOK (0.67) | MOKNPC1RAB9AL3MBTL1 | |
| SCHEMBL19475283 | 0.82 | MOK (0.75) | MOK | |
| SCHEMBL19475281 | 0.80 | MOK (0.68) | MOKNPC1RAB9ACYP2A13 | |
| SCHEMBL31590624 | 0.80 | MOK (0.68) | MOKNPC1RAB9ACYP2A13 | |
| SCHEMBL19475479 | 0.79 | MOK (0.74) | MOK | |
| SCHEMBL19475414 | 0.73 | MOK (0.70) | MOK | |
| SCHEMBL19475481 | 0.72 | MOK (0.57) | MOKJAK2 | |
| SCHEMBL19475494 | 0.72 | MOK (0.76) | MOK | |
| SCHEMBL19475361 | 0.72 | ACP1 (0.57) | MOKNPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | UNIV NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | UNIV NEW YORK (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | UNIV NEW YORK (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017184547-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017184547-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194136-A1 | QUINOLINE COMPOUNDS AS MODULATORS OF RAGE ACTIVITY AND USES THEREOF | AGER, HMGB1, GPR119 | MOK 4420/4885NPC1 3452/4885RAB9A 1174/4885 |
| US-11192859-B2 | Quinoline compounds as modulators of RAGE activity and uses thereof | AGER, HMGB1, GPR119 | MOK 4420/4885NPC1 3452/4885RAB9A 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.